A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Chan, S. L.; Furuse, J.; Galle, P. R.; Kelley, R. K.; Qin, S.; Armstrong, J.; Darilay, A.; Vlahovic, G.; Negro, A.; Sangro, B. |
| Abstract Title: | A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 237s |
| Language: | English |
| ACCESSION: | WOS:000442916007627 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.TPS4144 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS4144 -- Source: Wos |
